UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects

PloS one, 2014-11, Vol.9 (11), p.e111838-e111838

2014

Link zum Volltext

Verfügbarkeit prüfen

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase

PloS one, 2017-10, Vol.12 (10), p.e0186979-e0186979

2017

Link zum Volltext

Verfügbarkeit prüfen

Novel aspects of fibrin(ogen) fragments during inflammation

Molecular medicine (Cambridge, Mass.), 2011-05, Vol.17 (5-6), p.568-573

2011

Link zum Volltext

Verfügbarkeit prüfen

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran

Thrombosis research, 2016-06, Vol.142, p.44-51

2016

Link zum Volltext

Verfügbarkeit prüfen

Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

International journal of cancer, 2014-09, Vol.135 (6), p.1487-1496

2014

Link zum Volltext

Verfügbarkeit prüfen

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

Cells (Basel, Switzerland), 2022-10, Vol.11 (19), p.3180

2022

Link zum Volltext

Verfügbarkeit prüfen

BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I

Cancer medicine (Malden, MA), 2013-10, Vol.2 (5), p.611-624

2013

Link zum Volltext

Verfügbarkeit prüfen

Plasma Biomarkers of Myocardial Fibrosis and Remodeling in Terminal Heart Failure Patients Supported by Mechanical Circulatory Support Devices

The Journal of heart and lung transplantation, 2008-06, Vol.27 (6), p.589-596

2008

Link zum Volltext

Verfügbarkeit prüfen

Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

Circulation (New York, N.Y.), 2008-11, Vol.118 (20), p.2081-2090

2008

Link zum Volltext

Verfügbarkeit prüfen

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions

European journal of applied physiology, 2018-01, Vol.118 (1), p.195-203

2018

Link zum Volltext

Verfügbarkeit prüfen

Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders

Cardiovascular diabetology, 2009-11, Vol.8 (1), p.58-58, Article 58

2009

Link zum Volltext

Verfügbarkeit prüfen

Deguelin attenuates reperfusion injury and improves outcome after orthotopic lung transplantation in the rat

PloS one, 2012-06, Vol.7 (6), p.e39265-e39265

2012

Link zum Volltext

Verfügbarkeit prüfen

Myocardial transcriptome analysis of human arrhythmogenic right ventricular cardiomyopathy

Physiological genomics, 2012-01, Vol.44 (1), p.99-109

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3022-3022

2016

Link zum Volltext

Verfügbarkeit prüfen

A role for coagulation factor Xa in experimental pulmonary arterial hypertension

Cardiovascular research, 2011-10, Vol.92 (1), p.159-168

2011

Link zum Volltext

Verfügbarkeit prüfen

FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions

Expert opinion on pharmacotherapy, 2023-11, Vol.24 (17), p.1833-1837

2023

Link zum Volltext

Verfügbarkeit prüfen

What makes a good drug target?

Drug discovery today, 2011-12, Vol.16 (23), p.1037-1043

2011

Link zum Volltext

Verfügbarkeit prüfen

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

The lancet oncology, 2019-10, Vol.20 (10), p.1454-1466

2019

Link zum Volltext

Verfügbarkeit prüfen

What makes a good drug target?

Drug discovery today, 2012-02, Vol.17, p.S24-S30

2012

Link zum Volltext

Verfügbarkeit prüfen

Branched Chain Fatty Acids Induce Nitric Oxide-dependent Apoptosis in Vascular Smooth Muscle Cells

The Journal of biological chemistry, 2002-12, Vol.277 (51), p.49319-49325

2002

Link zum Volltext

Verfügbarkeit prüfen

Aberrant Oxidation of the Cholesterol Side Chain in Bile Acid Synthesis of Sterol Carrier Protein-2/Sterol Carrier Protein-x Knockout Mice

The Journal of biological chemistry, 1999-12, Vol.274 (50), p.35455-35460

1999

Link zum Volltext

Verfügbarkeit prüfen

Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein

Journal of lipid research, 1999-04, Vol.40 (4), p.708-714

1999

Link zum Volltext

Verfügbarkeit prüfen

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

International journal of cancer, 2019-09, Vol.145 (5), p.1346-1357

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4779: Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitro

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4779-4779

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(98)

Publikationsform

Artikel
(116)
Bücher
(2)
Reviews
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase

Novel aspects of fibrin(ogen) fragments during inflammation

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran

Regorafenib (BAY 73‐4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

Patient Selection Approaches in FGFR Inhibitor Trials—Many Paths to the Same End?

BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I

Plasma Biomarkers of Myocardial Fibrosis and Remodeling in Terminal Heart Failure Patients Supported by Mechanical Circulatory Support Devices

Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions

Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders

Deguelin attenuates reperfusion injury and improves outcome after orthotopic lung transplantation in the rat

Myocardial transcriptome analysis of human arrhythmogenic right ventricular cardiomyopathy

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

A role for coagulation factor Xa in experimental pulmonary arterial hypertension

FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions

What makes a good drug target?

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

What makes a good drug target?

Branched Chain Fatty Acids Induce Nitric Oxide-dependent Apoptosis in Vascular Smooth Muscle Cells

Aberrant Oxidation of the Cholesterol Side Chain in Bile Acid Synthesis of Sterol Carrier Protein-2/Sterol Carrier Protein-x Knockout Mice

Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

Abstract 4779: Rogaratinib, a small molecule pan-FGFR inhibitor potently inhibits FGFR4-phosphorylation and exerts anti-tumor efficacy in vivo and in vitro

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1 / 3 mRNA Expression

Suchergebnisse filtern